Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FROM TRIAL: In adults with acquired TTP, cap...
| מחבר ראשי: | |
|---|---|
| פורמט: | Journal article |
| שפה: | English |
| יצא לאור: |
Wiley
2019
|
| סיכום: | CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FROM TRIAL: In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP-related death and recurrence of TTP. |
|---|